SG11201403272YA - Compositions and methods for treating alzheimer's disease - Google Patents

Compositions and methods for treating alzheimer's disease

Info

Publication number
SG11201403272YA
SG11201403272YA SG11201403272YA SG11201403272YA SG11201403272YA SG 11201403272Y A SG11201403272Y A SG 11201403272YA SG 11201403272Y A SG11201403272Y A SG 11201403272YA SG 11201403272Y A SG11201403272Y A SG 11201403272YA SG 11201403272Y A SG11201403272Y A SG 11201403272YA
Authority
SG
Singapore
Prior art keywords
disease
compositions
methods
treating alzheimer
alzheimer
Prior art date
Application number
SG11201403272YA
Other languages
English (en)
Inventor
Neil R Cashman
Grant Mcclarty
Original Assignee
Cangene U S Inc
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cangene U S Inc, Univ British Columbia filed Critical Cangene U S Inc
Publication of SG11201403272YA publication Critical patent/SG11201403272YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201403272YA 2011-11-10 2012-11-12 Compositions and methods for treating alzheimer's disease SG11201403272YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161558430P 2011-11-10 2011-11-10
US201261589809P 2012-01-23 2012-01-23
US201213582308A 2012-08-31 2012-08-31
PCT/US2012/064722 WO2013071267A1 (fr) 2011-11-10 2012-11-12 Compositions et méthodes de traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
SG11201403272YA true SG11201403272YA (en) 2014-08-28

Family

ID=48290671

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201403272YA SG11201403272YA (en) 2011-11-10 2012-11-12 Compositions and methods for treating alzheimer's disease

Country Status (8)

Country Link
EP (1) EP2780082A4 (fr)
CN (1) CN104093454A (fr)
AU (1) AU2012335014A1 (fr)
CA (1) CA2855669A1 (fr)
EA (1) EA201491851A1 (fr)
HK (1) HK1201771A1 (fr)
SG (1) SG11201403272YA (fr)
WO (1) WO2013071267A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2644335C2 (ru) 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
EP3102611A4 (fr) * 2014-02-03 2017-08-23 Cangene Corporation Molécules de liaison à des bêta-amyloïdes humanisées et utilisations de celles-ci
WO2016008047A1 (fr) * 2014-07-14 2016-01-21 Cangene Corporation Vaccination peptidique cyclique pour le traitement de troubles liés à la protéine bêta-amyloïde
WO2016187339A1 (fr) * 2015-05-18 2016-11-24 Synaptec Development Llc Clairance de galantamine d'amyloides
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
EP3374380A4 (fr) * 2015-11-09 2019-05-15 The University Of British Columbia Épitopes en c-terminal dans la bêta-amyloïde et anticorps conformationnels sélectifs associés
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3004496A1 (fr) * 2015-11-09 2017-05-18 Neil R. Cashman Epitopes dans la beta-amyloide et anticorps conformationnels selectifs associes
CA3004494A1 (fr) * 2015-11-09 2017-05-18 The University Of British Columiba Epitopes dans la region centrale de la beta-amyloide et anticorps conformationnels selectifs associes
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN112661828B (zh) * 2021-01-15 2022-04-01 武汉大学 一种突触素的抗原肽及其抗体与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045555B2 (en) * 2008-07-01 2015-06-02 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
US20110306605A1 (en) * 2008-12-22 2011-12-15 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds for the treatment of alzheimer's disease and cancer
KR20130043088A (ko) * 2010-02-09 2013-04-29 브리스톨-마이어스 스큅 컴퍼니 면역검정 표준물 및 검정내 보정 표준물을 사용한 임상 바이오마커의 측정
RU2644335C2 (ru) * 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
WO2016008047A1 (fr) * 2014-07-14 2016-01-21 Cangene Corporation Vaccination peptidique cyclique pour le traitement de troubles liés à la protéine bêta-amyloïde

Also Published As

Publication number Publication date
CA2855669A1 (fr) 2013-05-16
EP2780082A1 (fr) 2014-09-24
WO2013071267A1 (fr) 2013-05-16
CN104093454A (zh) 2014-10-08
AU2012335014A1 (en) 2014-06-19
HK1201771A1 (en) 2015-09-11
EP2780082A4 (fr) 2015-08-05
EA201491851A1 (ru) 2015-12-30

Similar Documents

Publication Publication Date Title
EP2707369A4 (fr) Compositions et procédés pour traiter la maladie d'alzheimer
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
ZA201406209B (en) Methods and compositions for treating huntington's disease
SMT201800678T1 (it) Composizioni farmaceutiche per il trattamento del morbo di alzheimer
IL236054A0 (en) Compositions and methods for treating Crohn's disease and related conditions and infections
EP2655334A4 (fr) Compositions et méthodes utilisables en vue du traitement de maladies
IL229257A0 (en) Preparations and methods for the treatment of diseases related to the retina of the eye
EP2621588A4 (fr) Procédés et compositions pour le traitement de maladie en utilisant l'inhalation
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
DK3292875T3 (en) Compositions and methods for treating diseases
ZA201404676B (en) Compositions and methods for treating metabolic disorders
ZA201404187B (en) Compositions and methods for treating dental conditions
IL231158A0 (en) Preparations and methods for the treatment of neurodegenerative diseases
IL231157A0 (en) Preparations and methods for the treatment of neurodegenerative diseases
EP2485733A4 (fr) Procédés pour le traitement de la maladie d'alzheimer
EP2766728A4 (fr) Compositions et méthodes de traitement et de prévention d'une coronaropathie
SMT201800249T1 (it) Composizioni e metodi per trattare la malattia celiaca
GB2496801B (en) A method of treating alzheimer's disease
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
IL217149A0 (en) Compositions and methods for treating parkinson's disease
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
ZA201207226B (en) Compositions and methods for treating viral diseases
SG11201402899TA (en) Methods and compositions for treating viral diseases
HK1195902A (en) Compositions and methods for treating alzheimer's disease
PL2593129T3 (pl) Nonapeptyd pat do stosowania w leczeniu choroby alzheimera